Headquartered in South San Francisco, CA Fiscal year ends September NASDAQ: TWST twistbioscience.com
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells customizable DNA-based products across the biological continuum. The company operates through two primary segments: DNA Synthesis and Protein Solutions (DSPS), which provides synthetic oligos, genes, proteins, libraries, and antibody discovery solutions; and NGS Applications, which delivers next-generation sequencing workflow tools including target enrichment panels and library preparation products. Twist serves customers in diagnostics, therapeutics, industrial applications, agriculture, and research markets. The company's silicon-based DNA writing platform enables high-throughput, precise synthesis at scale. Twist also offers characterization data and complex gene synthesis capabilities. The company previously spun out its Atlas Data Storage subsidiary. Twist trades on the NASDAQ under the ticker TWST. Updated
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Pre-Market Stock Futures: Futures are exploding higher on news of a peace deal with Iran expected to be signed this Friday. This follows a historic Friday that saw the coming-out party of…
Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI…
Cathie Wood’s Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary…
The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The tech sector has been the driving force for the stock market’s gains…
Wednesday's top analyst upgrades and downgrades included Amazon, AMC Entertainment, Apollo Global Management, Apple, Block, Capital One Financial, Carlyle, CVS Health, Etsy, Fox, Gilead Sciences, Goldman Sachs, GSK, PayPal, Tesla, T-Mobile, U.S.…
Tuesday’s top analyst upgrades and downgrades included Coursera, CSX, Carvana, FedEx, Fox, Marathon, Petro China, Planet Fitness, Regeneron and Rackspace.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells customizable DNA-based products across the biological continuum.
The Wall Street consensus 12-month price target for TWST is $150.33.
